147 filings
8-K
ALDX
Aldeyra Therapeutics Inc
28 Mar 24
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
7:01am
8-K
ALDX
Aldeyra Therapeutics Inc
13 Feb 24
Regulation FD Disclosure
4:00pm
8-K
ALDX
Aldeyra Therapeutics Inc
4 Jan 24
Other Events
7:00am
8-K
ALDX
Aldeyra Therapeutics Inc
21 Dec 23
Other Events
4:06pm
8-K
ALDX
Aldeyra Therapeutics Inc
19 Dec 23
Regulation FD Disclosure
7:05am
8-K
mqkep5ush16pigev09
28 Nov 23
Regulation FD Disclosure
7:16am
8-K
yl5i wseou04k7ae
1 Nov 23
Entry into a Material Definitive Agreement
7:09am
8-K
9k4voe apo7zce
16 Oct 23
Other Events
8:00am
8-K
1gsfvbgy
3 Jul 23
Submission of Matters to a Vote of Security Holders
4:07pm
8-K
5bmncm05
29 Jun 23
Regulation FD Disclosure
7:01am
8-K
2yiu v8nsep804a
27 Jun 23
Regulation FD Disclosure
7:01am
8-K
k7qddgnsd zuy0uv1
21 Jun 23
Other Events
4:25pm
8-K
wrqlo98pyn1pqs8qj 9m
15 Jun 23
Regulation FD Disclosure
7:01am
8-K
qi0nmcun
4 May 23
Results of Operations and Financial Condition
7:05am
8-K
bf3a81 m8to0b
10 Mar 23
Regulation FD Disclosure
4:53pm
8-K
z9lgzd5h1j1b4
9 Mar 23
Results of Operations and Financial Condition
7:05am
8-K
30dz1m4 kw3k1ca7rfhr
2 Mar 23
Planned U.S. Launch of ADX-2191 in Second Half of 2023, Pending Approval by the FDA
7:05am
8-K
e7iasji9uw8y36nx4hq
7 Feb 23
Other Events
7:05am
8-K
tlhlp9kf61xumza2
27 Dec 22
Entry into a Material Definitive Agreement
7:00am
8-K
8jflqu bemlaufb4r558
21 Dec 22
Other Events
7:05am